

1 **Supporting information for** 2 **“Co-infections by non-interacting** 3 **pathogens are not independent &** 4 **require new tests of interaction”**

5 **Frédéric M. Hamelin, Linda J.S. Allen, Vrushali A. Bokil, Louis J. Gross,**
6 **Frank M. Hilker, Michael J. Jeger, Carrie A. Manore, Alison G. Power,**
7 **Megan A. Rúa, Nik J. Cunniffe**

8 **Organisation of this document**

9 Supplementary Information S1 (“Mathematical supplements”) contains five subsec-
10 tions:

- 11 • S1.1. “Formal proof that the proportion of co-infected hosts is larger than the
12 product of the prevalences”.
 - 13 – A demonstration that $J_{1,2}$ from Eq. (3) in the Main Text is larger than $P = I_1 I_2$
14 as can be derived from Eq. (1) in the Main Text for all parameters (for
15 sufficiently large t).
- 16 • S1.2. “Covariance matrix at the endemic equilibrium”.
 - 17 – A derivation of the covariance matrix for stochastic fluctuations around the
18 endemic equilibrium in the two-pathogen model (leads to Eq. (27) in the
19 main text).
- 20 • S1.3. “Comments on the model of May and Nowak (1995)”.
 - 21 – Details how the often-cited co-infection model of May and Nowak (1995) is
22 not correct.
- 23 • S1.4. “Extending the models to accommodate specific clearance”.
 - 24 – Shows how the methods developed in the main text can be extended to
25 accommodate an additional epidemiological parameter: specific clearance

26 (i.e. each pathogen being cleared independently of any other, possibly at
27 a pathogen-specific rate).

- 28 • S1.5. “The prevalence of co-infections can be equal to the product of the preva-
29 lences of interacting pathogens”.

- 30 – Shows how, in the model described in Supplementary Information, Section
31 S1.4, if there is no host renewal (removal or unspecific clearance) but only
32 specific clearance, then the prevalence of co-infections can be equal to the
33 product of the prevalences even when pathogens interact. This comple-
34 ments our main point (non-interaction does not imply independence) by
35 showing that it holds the other way around as well (independence does not
36 imply non-interaction).

37 Supplementary Information S2 (“Sources of data and side results of model fit-
38 ting”) contains three subsections:

- 39 • S2.1. “Additional fitting of the NiSP model”.

- 40 – Results of fitting the NiSP model to three additional data sets not consid-
41 ered in the main text. These studies do not concern a single pathogen
42 species, and so the pragmatic assumption of epidemiological interchange-
43 ability between pathogens is less justifiable.

- 44 • S2.2. “Fitting the NiDP model”.

- 45 – Re-tabulates the data sets used by Howard et al. (2001), and describes in
46 full how our criteria to allow a study to be considered led to us fixing on 41
47 particular studies to analyse.

- 48 • S2.3. “Fitting the models with specific clearance”.

- 49 – Shows that fitting the NiSP model with specific clearance confirms results
50 found from a model that does not include specific clearance as an addi-
51 tional parameter.

52 **S1 Mathematical supplements**

53 **S1.1 Formal proof that the proportion of co-infected hosts is larger** 54 **than the product of the prevalences**

55 Let $P = I_1 I_2$ and introduce the new variable Z , the extent to which the product of
56 prevalences over-estimates the proportion of co-infected hosts,

$$Z = P - J_{1,2} = I_1 I_2 - J_{1,2}. \quad (\text{S1})$$

57 Differentiating Z and simplifying using Eqs. (2) and (3) in the main text leads to

$$\begin{aligned} \dot{Z} &= I_1 \dot{I}_2 + I_2 \dot{I}_1 - \dot{J}_{1,2}, \\ \dot{Z} &= -(\beta_1 I_1 + \beta_2 I_2 + \mu)Z - \mu P. \end{aligned} \quad (\text{S2})$$

58 Of interest is the sign of $Z(t)$ as a function of its initial conditions. We assume
59 $R_{0,i} > 1$ and $0 < I_i(0) \leq \bar{I}_i$ for $i = 1, 2$. The differential equation for I_i is logistic and
60 therefore, $I_i(t)$ converges monotonically to \bar{I}_i , $i = 1, 2$. There exists $\epsilon > 0$ such that
61 $P(t) > \tilde{P} = \bar{I}_1 \bar{I}_2 - \epsilon > 0$ for $t \geq 0$. Suppose $Z(0) > 0$. The term $-\mu P(t) < -\mu \tilde{P} < 0$
62 ensures that $Z(t)$ decreases to zero in finite time. Let t_1 be the first time that $Z(t_1) =$
63 0 . Then $\dot{Z}(t_1) < 0$, so $Z(t)$ eventually becomes negative. To show that $Z(t)$ remains
64 negative, let $Z(t) < 0$ for $t_1 < t < t_2$ and let t_2 be the first time that $Z(t_2) = 0$, then
65 $\dot{Z}(t_2) \geq 0$, a contradiction to the fact that $\dot{Z}(t_2) \leq -\mu \tilde{P}$. Hence $Z(t)$ remains negative
66 for $t > t_1$. In a similar manner it can be shown that if $Z(0) = 0$ or $Z(0) < 0$, then
67 $Z(t) < 0$ for $t > 0$. In particular, due to the convergence of $I_i(t)$ to \bar{I}_i for $i = 1, 2$, $Z(t)$
68 converges to the negative limit: $-\mu \bar{I}_1 \bar{I}_2 / (\beta_1 \bar{I}_1 + \beta_2 \bar{I}_2 + \mu)$.

69 In summary, the fate of Z is to become negative in finite time and to remain
70 negative. This is due to $\mu > 0$. Otherwise for $\mu = 0$, Z would not change sign and
71 would asymptotically converge to zero.

72 **S1.2 Covariance matrix at the endemic equilibrium**

73 In the stochastic version of the model, the fluctuations $(\Delta I_1, \Delta I_2) = (I_1 - \bar{I}_1, I_2 - \bar{I}_2)$
74 about the endemic equilibrium $(\bar{I}_1, \bar{I}_2) = N(1 - 1/R_{0,1}, 1 - 1/R_{0,2})$ can be approximated

75 by the solution of the linear multivariate Fokker-Planck equation,

$$\frac{\partial p(\mathbf{x}, t)}{\partial t} = - \sum_{i,j=1}^2 A_{ij} \frac{\partial(x_j p)}{\partial x_i} + \frac{1}{2} \sum_{i,j=1}^2 B_{ij} \frac{\partial^2 p}{\partial x_i \partial x_j}, \quad (\text{S3})$$

76 where the vector $\mathbf{x} = (x_1, x_2)$ corresponds to $(\Delta I_1, \Delta I_2)$. The steady-state solution of
 77 this equation is a Gaussian distribution with mean zero and covariance matrix \bar{C} .
 78 We will use this multivariate normal distribution to approximate the joint probability
 79 density function of the random variables (I_1, I_2) near the endemic equilibrium. Matrix
 80 $A = [A_{ij}]$ is the rate of change toward zero and matrix $B = [B_{ij}]$ is the covariance
 81 of this process (O’Dea et al., 2018; Van Kampen, 1992). In particular, matrix A is
 82 the linearization of the differential equations for (I_1, I_2) (total population size, not
 83 proportions) about the endemic equilibrium,

$$A = \begin{bmatrix} \beta_1 - 2\frac{\beta_1}{N}\bar{I}_1 - \mu & 0 \\ 0 & \beta_2 - 2\frac{\beta_2}{N}\bar{I}_1 - \mu \end{bmatrix} = \begin{bmatrix} -\beta_1 + \mu & 0 \\ 0 & -\beta_2 + \mu \end{bmatrix}. \quad (\text{S4})$$

84 We use the fact that $I_1 = J_1 + J_{1,2}$ and $I_2 = J_2 + J_{1,2}$ and sum the appropriate elements
 85 in the covariance matrix Σ (Eq. (24) in the main text) to compute the covariance
 86 matrix B ,

$$B = \begin{bmatrix} \bar{F}_1(\bar{J}_\emptyset + \bar{J}_2) + \mu\bar{I}_1 & \mu\bar{J}_{12} \\ \mu\bar{J}_{12} & \bar{F}_2(\bar{J}_\emptyset + \bar{J}_1) + \mu\bar{I}_2 \end{bmatrix} = \begin{bmatrix} 2N\mu\left(1 - \frac{1}{R_{0,1}}\right) & \mu\bar{J}_{12} \\ \mu\bar{J}_{12} & 2N\mu\left(1 - \frac{1}{R_{0,2}}\right) \end{bmatrix} \quad (\text{S5})$$

87 The expressions in matrices A and B are evaluated at the endemic equilibrium. In
 88 particular, $\bar{F}_i = \beta_i \bar{I}_i / N = \beta_i (1 - 1/R_{0,i})$, $i = 1, 2$, and the equilibrium \bar{J}_{12} is found by
 89 multiplying Eq. (9) in the main text by N :

$$\bar{J}_{12} = \left(\frac{N(\beta_1 + \beta_2)}{\beta_1 + \beta_2 - \mu} \right) \left(1 - \frac{1}{R_{0,1}} \right) \left(1 - \frac{1}{R_{0,2}} \right). \quad (\text{S6})$$

90 Van Kampen (1992) showed that the covariance matrix C of the Fokker-Planck
 91 equation is the solution of the differential equation: $\dot{C} = AC + CA^T + B$. The steady-
 92 state covariance matrix is the solution of

$$AC + CA^T = -B. \quad (\text{S7})$$

93 To compute the steady-state covariance matrix for the proportion of the population
 94 that is infected, divide the solution of Eq. (S7) by N^2 . That is, \bar{C} equals

$$\bar{C} = \frac{1}{N^2} \begin{bmatrix} \frac{N\mu(1-\frac{1}{R_{0,1}})}{\beta_1-\mu} & \frac{\mu\bar{J}_{1,2}}{(\beta_1-\mu)+(\beta_2-\mu)} \\ \frac{\mu\bar{J}_{1,2}}{(\beta_1-\mu)+(\beta_2-\mu)} & \frac{N\mu(1-\frac{1}{R_{0,2}})}{\beta_2-\mu} \end{bmatrix} = \begin{bmatrix} \frac{1}{NR_{0,1}} & \frac{\mu\bar{J}_{1,2}}{N^2[(\beta_1-\mu)+(\beta_2-\mu)]} \\ \frac{\mu\bar{J}_{1,2}}{N^2[(\beta_1-\mu)+(\beta_2-\mu)]} & \frac{1}{NR_{0,2}} \end{bmatrix}, \quad (\text{S8})$$

95 where \bar{J}_{12} is defined in Eq. (S6). The steady-state covariance matrix in Eq. (S8) is
 96 used to construct confidence ellipses about the endemic equilibrium $(\bar{I}_1/N, \bar{I}_2/N) =$
 97 $(1 - 1/R_{0,1}, 1 - 1/R_{0,2})$ (as shown in Fig. 2C in the main text).

98 Note that the covariance between the prevalences of pathogen 1 and pathogen
 99 2 (the off-diagonal elements in Eq. (S8)) is

$$\bar{C}_{ij} = \text{cov}\left(\frac{I_1}{N}, \frac{I_2}{N}\right) = \frac{\mu\bar{J}_{1,2}}{N^2[(\beta_1-\mu)+(\beta_2-\mu)]} = \frac{(\beta_1+\beta_2)(\beta_1-\mu)(\beta_2-\mu)\mu}{N\beta_1\beta_2(\beta_1+\beta_2-\mu)(\beta_1-\mu+\beta_2-\mu)} \geq 0, \quad (\text{S9})$$

100 (for $i \neq j$) with equality if and only if $\mu = 0$ (assuming $\beta_i > \mu$, $i = 1, 2$).

101 **S1.3 Comments on the model of May and Nowak (1995)**

102 May and Nowak (1995) introduced a co-infection model very similar to that pre-
 103 sented in the main text, taking

$$\dot{I}_i = I_i[\beta_i(1-I_i) - \nu - \bar{\alpha}_i], \quad \text{with } i = 1, \dots, n, \quad (\text{S10})$$

104 for n pathogens. The natural mortality rate of the host is ν . The only difference from
 105 our model is pathogen-specific mortality. In a single infection, pathogen i induces
 106 an additional removal rate to the host α_i : this is the virulence of pathogen i . The
 107 induced removal rate of co-infected hosts is assumed to be equal to the maximum
 108 virulence of the co-infecting pathogens. The pathogens are ranked such that for all
 109 i , $\alpha_i < \alpha_{i+1}$. Pathogen 1 is the least virulent pathogen and n is the most virulent
 110 pathogen. The term $\bar{\alpha}_i$ denotes the average induced removal rate of hosts infected
 111 by pathogen i .

112 The authors state that the probability that a host is not infected with a pathogen

113 more virulent than i is defined as:

$$p_i = \prod_{j=i+1}^n (1 - I_j). \quad (\text{S11})$$

114 It is important to notice that an underlying assumption of this definition is that the dy-
 115 namics of the pathogens are independent. But, as we show below, they are not, since
 116 the most virulent pathogens influence the dynamics of least virulent pathogens. The
 117 coupling term $\bar{\alpha}_i$ is defined as:

$$\bar{\alpha}_i = \alpha_i p_i + \sum_{j=i+1}^n \alpha_j I_j p_j. \quad (\text{S12})$$

118 The term $I_j p_j$ represents the probability to be infected by j and uninfected by more
 119 virulent pathogens than j . Again, this definition implicitly assumes that the dynam-
 120 ics of the pathogens are independent. This seems to contradict the fact that the
 121 dynamics are coupled through virulence.

122 In this section, we check the model given in Eq. (S10) for $n = 2$ pathogens
 123 and show that the above definitions do not hold up to mathematical analysis. We
 124 consider the same 2-pathogen model as Eq. (3) of the main text, except that we
 125 include virulence parameters $\alpha_2 > \alpha_1$. Model (S10) is to be compared with:

$$\begin{aligned} \dot{J}_1 &= F_1 J_\emptyset - (F_2 + \nu + \alpha_1) J_1, \\ \dot{J}_2 &= F_2 J_\emptyset - (F_1 + \nu + \alpha_2) J_2, \\ \dot{J}_{1,2} &= F_2 J_1 + F_1 J_2 - (\nu + \max(\alpha_1, \alpha_2)) J_{1,2}, \\ &= F_2 J_1 + F_1 J_2 - (\nu + \alpha_2) J_{1,2}, \end{aligned} \quad (\text{S13})$$

126 where $J_\emptyset = 1 - J_1 - J_2 - J_{1,2}$.

127 Since model (S10) and model (S13) share the same biological assumptions and
 128 the same mathematical formalism, they should be equivalent (for $n = 2$ pathogens).
 129 Let $I_1 = J_1 + J_{1,2}$ and $I_2 = J_2 + J_{1,2}$. Model (S13) is equivalent to

$$\begin{aligned} \dot{I}_1 &= \beta_1 I_1 (1 - I_1) - (\nu + \alpha_1^*) I_1, \\ \dot{I}_2 &= \beta_2 I_2 (1 - I_2) - (\nu + \alpha_2) I_2, \\ \dot{J}_{1,2} &= \beta_1 I_1 (I_2 - J_{1,2}) + \beta_2 I_2 (I_1 - J_{1,2}) - (\nu + \alpha_2) J_{1,2}, \end{aligned} \quad (\text{S14})$$

130 where

$$\alpha_1^* = \alpha_1 \left(1 - \frac{J_{1,2}}{I_1}\right) + \alpha_2 \frac{J_{1,2}}{I_1}.$$

131 Eq. (S11) yields $p_1 = 1 - I_2$ and $p_2 = 1$. Eq. (S12) yields

$$\bar{\alpha}_1 = \alpha_1(1 - I_2) + \alpha_2 I_2.$$

132 For model (S10) and model (S13) to coincide, one must have $\alpha_1^* = \bar{\alpha}_1$, i.e. $J_{1,2} =$
133 $I_1 I_2$. Proceeding as in Supplementary Information, Section S1.1, let $P = I_1 I_2$ and
134 $Z = P - J_{1,2}$. We have

$$\dot{Z} = -(\beta_1 I_1 + \beta_2 I_2 + \nu + \alpha_2)Z - (\nu + \alpha_1^*)P.$$

135 Assuming $P(t) > \tilde{P} > 0$ for $t > 0$, it can be shown that $Z(t)$ becomes negative and
136 stays negative, implying for some time t_0 and $t > t_0$, $J_{1,2}(t) > P(t) = I_1(t)I_2(t)$.
137 Therefore, $\alpha_1^* \neq \bar{\alpha}_1$. Hence, model (S10) and model (S13) are not equivalent, as they
138 should be, if model (S10) is correct.

139 **S1.4 Extending the models to accommodate specific clearance**

140 **S1.4.1 Two-pathogen model**

141 Introducing a pathogen-specific clearance rate γ_i , Eq. (1) of the main text is replaced
142 by

$$\dot{I}_i = \beta_i I_i (1 - I_i) - (\gamma_i + \mu) I_i \quad (\text{S15})$$

143 and Eq. (3) by

$$\begin{aligned} \dot{J}_1 &= F_1 J_\emptyset - (F_2 + \gamma_1 + \mu) J_1 + \gamma_2 J_{1,2}, \\ \dot{J}_2 &= F_2 J_\emptyset - (F_1 + \gamma_2 + \mu) J_2 + \gamma_1 J_{1,2}, \\ \dot{J}_{1,2} &= F_2 J_1 + F_1 J_2 - (\gamma_1 + \gamma_2 + \mu) J_{1,2}, \end{aligned} \quad (\text{S16})$$

144 where the definition of F_i is the same as in Eq. (2). The parameter μ (host renewal)
145 is unchanged: this is the sum of the death rate and the unspecific clearance rate for
146 infected hosts.

147 After inclusion of pathogen-specific clearance rates, Eq. (7) is replaced by

$$\dot{J}_\emptyset = \mu(J_1 + J_2 + J_{1,2}) - (F_1 + F_2)J_\emptyset + \gamma_1 J_1 + \gamma_2 J_2 = \mu(1 - J_\emptyset) - (F_1 + F_2)J_\emptyset + \gamma_1 J_1 + \gamma_2 J_2. \quad (\text{S17})$$

148 and the basic reproduction number is

$$R_{0,i} = \frac{\beta_i}{\gamma_i + \mu}. \quad (\text{S18})$$

149 Also, Eq. (8) is replaced by

$$\dot{J}_{1,2} = \beta_2 I_2 (I_1 - J_{1,2}) + \beta_1 I_1 (I_2 - J_{1,2}) - (\gamma_1 + \gamma_2 + \mu) J_{1,2}. \quad (\text{S19})$$

150 Eq. (9) is unchanged as the relative deviation from statistical independence is unaffected by the specific clearance rates γ_i .

152 Finally, Eq. (S2) is replaced by

$$\dot{Z} = -(\beta_1 I_1 + \beta_2 I_2 + \gamma_1 + \gamma_2 + \mu)Z - \mu P. \quad (\text{S20})$$

153 where $Z(t)$ converges to the negative limit: $-\mu \bar{I}_1 \bar{I}_2 / (\beta_1 \bar{I}_1 + \beta_2 \bar{I}_2 + \gamma_1 + \gamma_2 + \mu)$. Again,
154 the fate of Z is to become negative in finite time and to remain negative provided
155 $\mu > 0$.

156 **S1.4.2 Analysis of the n -pathogen model**

157 Introducing the notation for the set of hosts infected by one additional pathogen

158 $\Lambda_i = \Gamma \cup \{i\}$ (for $i \notin \Gamma$), Eq. (5) in the main text becomes

$$\dot{J}_\Gamma = \sum_{i \in \Gamma} F_i J_{\Omega_i} - \left(\sum_{i \notin \Gamma} F_i + \sum_{i \in \Gamma} \gamma_i + \mu \right) J_\Gamma + \sum_{i \notin \Gamma} \gamma_i J_{\Lambda_i}. \quad (\text{S21})$$

159 with F_i the same as in Eq. (6). The final term in Eq. (S21) tracks the inflow due
160 to hosts with one additional infection that clear a single infection. This final term is
161 omitted in the single case in which Γ corresponds to infection by all pathogens. Also,
162 the updated version of Eq. (10) for \dot{J}_\emptyset with pathogen-specific clearance rates is

$$\dot{J}_\emptyset = \mu(1 - J_\emptyset) - \left(\sum_{i=1}^n F_i \right) J_\emptyset + \sum_{i=1}^n \gamma_i J_i. \quad (\text{S22})$$

163 **Equilibrium analysis.** The equilibrium equations with pathogen-specific clearance
 164 rates are

$$0 = \sum_{i \in \Gamma} \bar{F}_i \bar{J}_{\Omega_i} - \left(\sum_{i \notin \Gamma} \bar{F}_i + \sum_{i \in \Gamma} \gamma_i + \mu \right) \bar{J}_{\Gamma} + \sum_{i \notin \Gamma} \gamma_i \bar{J}_{\Lambda_i}, \quad (\text{S23})$$

165 and

$$0 = \sum_{i \in \Gamma} (\beta_i - (\gamma_i + \mu)) \bar{J}_{\Omega_i} - \left(\sum_{i \notin \Gamma} (\beta_i - (\gamma_i + \mu)) + \sum_{i \in \Gamma} \gamma_i + \mu \right) \bar{J}_{\Gamma} + \sum_{i \notin \Gamma} \gamma_i \bar{J}_{\Lambda_i}. \quad (\text{S24})$$

166 with

$$\bar{F}_i = \beta_i \bar{I}_i = \beta_i \left(1 - \frac{\gamma_i + \mu}{\beta_i} \right) = \beta_i - (\gamma_i + \mu). \quad (\text{S25})$$

167 (replacing Eqs. (11-12-13)).

168 To fit the models to data, it would be necessary to scale by the rate of host
 169 renewal μ in Eq. (S24), leading to

$$0 = \sum_{i \in \Gamma} (\hat{\beta}_i - (\hat{\gamma}_i + 1)) \bar{J}_{\Omega_i} - \left(\sum_{i \notin \Gamma} (\hat{\beta}_i - (\hat{\gamma}_i + 1)) + \sum_{i \in \Gamma} \hat{\gamma}_i + 1 \right) \bar{J}_{\Gamma} + \sum_{i \notin \Gamma} \hat{\gamma}_i \bar{J}_{\Lambda_i}, \quad (\text{S26})$$

170 and so consider infection ($\hat{\beta}_i = \beta_i/\mu$) and specific clearance ($\hat{\gamma}_i = \gamma_i/\mu$) rates mea-
 171 sured relative to the rate of host renewal. With the scaled force of infection at
 172 equilibrium

$$\hat{F}_i = \hat{\beta}_i - (\hat{\gamma}_i + 1), \quad (\text{S27})$$

173 then Eq. (S26) can be written as

$$0 = \sum_{i \in \Gamma} \hat{F}_i \bar{J}_{\Omega_i} - \left(\sum_{i \notin \Gamma} \hat{F}_i + \sum_{i \in \Gamma} \hat{\gamma}_i + 1 \right) \bar{J}_{\Gamma} + \sum_{i \notin \Gamma} \hat{\gamma}_i \bar{J}_{\Lambda_i}. \quad (\text{S28})$$

174 Given the values of $\hat{\beta}_i$ and $\hat{\gamma}_i$, the $2^n - 1$ linear equations corresponding to Eq. (S28)
 175 can be solved simultaneously with the corresponding equation for the equilibrium
 176 density of uninfected hosts (i.e. the scaled version of Eq. (S22)):

$$-1 = - \left(\sum_{i=1}^n \hat{F}_i + 1 \right) \bar{J}_{\emptyset} + \sum_{i=1}^n \hat{\gamma}_i \bar{J}_i. \quad (\text{S29})$$

177 to find all 2^n equilibrium prevalences predicted by the n -pathogen model. How-
 178 ever, since the recursive solution presented in the main text (Eq. (16)) is no longer
 179 available, the system must be solved using (standard) numerical methods for linear

180 systems of equations.

181 **Worked example.** When $n = 3$ there is a total of $2^3 = 8$ classes of hosts, un-
 182 infected (J_\emptyset), singly-infected (J_1, J_2 and J_3), doubly-infected ($J_{1,2}, J_{1,3}$ and $J_{2,3}$) and
 183 triply-infected ($J_{1,2,3}$). The equilibrium prevalences can be concatenated into a sin-
 184 gle vector, given here in lexicographical order

$$\mathbf{v} = [\bar{J}_\emptyset, \bar{J}_1, \bar{J}_2, \bar{J}_3, \bar{J}_{1,2}, \bar{J}_{1,3}, \bar{J}_{2,3}, \bar{J}_{1,2,3}]^T. \quad (\text{S30})$$

185 If we define \mathbf{b} as

$$\mathbf{b} = [-1, 0, 0, 0, 0, 0, 0, 0]^T, \quad (\text{S31})$$

186 then Eq. (S28) and (S29) are equivalent to the system of 8 linear equations

$$H\mathbf{v} = \mathbf{b}, \quad (\text{S32})$$

in which matrix H equals

$$\begin{bmatrix} -(\hat{f}_1 + \hat{f}_2 + \hat{f}_3 + 1) & \hat{\gamma}_1 & \hat{\gamma}_2 & \hat{\gamma}_3 & 0 & 0 & 0 & 0 \\ \hat{f}_1 & -(\hat{f}_2 + \hat{f}_3 + \hat{\gamma}_1 + 1) & 0 & 0 & \hat{\gamma}_2 & \hat{\gamma}_3 & 0 & 0 \\ \hat{f}_2 & 0 & -(\hat{f}_1 + \hat{f}_3 + \hat{\gamma}_2 + 1) & 0 & \hat{\gamma}_1 & 0 & \hat{\gamma}_3 & 0 \\ \hat{f}_3 & 0 & 0 & -(\hat{f}_1 + \hat{f}_2 + \hat{\gamma}_3 + 1) & 0 & \hat{\gamma}_1 & \hat{\gamma}_2 & 0 \\ 0 & \hat{f}_2 & \hat{f}_1 & 0 & -(\hat{f}_3 + \hat{\gamma}_1 + \hat{\gamma}_2 + 1) & 0 & 0 & \hat{\gamma}_3 \\ 0 & \hat{f}_3 & 0 & \hat{f}_1 & 0 & -(\hat{f}_2 + \hat{\gamma}_1 + \hat{\gamma}_3 + 1) & 0 & \hat{\gamma}_2 \\ 0 & 0 & \hat{f}_3 & \hat{f}_2 & 0 & 0 & -(\hat{f}_1 + \hat{\gamma}_2 + \hat{\gamma}_3 + 1) & \hat{\gamma}_1 \\ 0 & 0 & 0 & 0 & \hat{f}_3 & \hat{f}_2 & \hat{f}_1 & -(\hat{\gamma}_1 + \hat{\gamma}_2 + \hat{\gamma}_3 + 1) \end{bmatrix}$$

187 The equilibrium prevalence of hosts infected by any combination of pathogens can
 188 then be obtained by solving Eq. (S32) for \mathbf{v} .

189 **Proof that there is always a unique equilibrium.** For the case $n = 3$ pathogens,
 190 the matrix $-H$ has off-diagonal entries that are non-positive and diagonal entries that
 191 are strictly positive. In addition, the absolute value of each diagonal entry is strictly
 192 greater than the absolute value of the sum of all of the other entries in that column.
 193 These properties of $-H$ make it a non-singular M-matrix. (Properties of an M-matrix
 194 are given in (Plemmons, 1977).) As a consequence of these properties, $-H^{-1}$ exists
 195 and is a non-negative matrix from which it follows that the solution \mathbf{v} in Eq. (S32) is

196 non-negative and can be expressed as

$$\mathbf{v} = H^{-1}\mathbf{b}. \quad (\text{S33})$$

197 Generalizing to the case of n pathogens, it can be verified that matrix $-H$ in Eq. (S32)
 198 will still have the same properties, making it a non-singular M-matrix and therefore,
 199 the equilibrium \mathbf{v} is the unique non-negative solution given by Eq. (S33).

200 **S1.4.3 Relationship between the NiDP and multinomial models**

201 In this subsection, we show that the equilibrium prevalences in the NiDP model with
 202 $\mu = 0$ are equal to the expectations under statistical independence, i.e.,

$$\bar{J}_\Gamma = \prod_{i \in \Gamma} \bar{I}_i \prod_{j \notin \Gamma} (1 - \bar{I}_j), \quad (\text{S34})$$

203 where $\bar{I}_i = 1 - \gamma_i/\beta_i$ for all $i \in \{1, 2, \dots, n\}$. In other words, when there is no infected
 204 host renewal (removal or unspecific clearance), the probability to be infected by a
 205 set of pathogens Γ follows a multinomial distribution with parameters n (the number
 206 of distinct pathogens) and $p_i = \bar{I}_i$ for all $i \in \{1, 2, \dots, n\}$.

207 In the specific case $\mu = 0$, Eq. (S23) becomes

$$0 = \sum_{i \in \Gamma} \bar{F}_i \bar{J}_{\Omega_i} - \left(\sum_{i \notin \Gamma} \bar{F}_i + \sum_{i \in \Gamma} \gamma_i \right) \bar{J}_\Gamma + \sum_{i \notin \Gamma} \gamma_i \bar{J}_{\Lambda_i}, \quad (\text{S35})$$

208 with $\bar{F}_i = \beta_i - \gamma_i$. Eq. (S34) implies

$$\bar{J}_{\Omega_i} = \bar{J}_\Gamma \frac{1 - \bar{I}_i}{\bar{I}_i}, \quad \text{and} \quad \bar{J}_{\Lambda_i} = \bar{J}_\Gamma \frac{\bar{I}_i}{1 - \bar{I}_i}. \quad (\text{S36})$$

Substituting the values in Eq. (S36) into the right side of Eq. (S35),

$$\sum_{i \in \Gamma} \left(\bar{F}_i \frac{1 - \bar{I}_i}{\bar{I}_i} \right) - \left(\sum_{i \notin \Gamma} \bar{F}_i + \sum_{i \in \Gamma} \gamma_i \right) + \sum_{i \notin \Gamma} \gamma_i \frac{\bar{I}_i}{1 - \bar{I}_i}$$

and simplifying leads to

$$\sum_{i \in \Gamma} \left((\beta_i - \gamma_i) \frac{\gamma_i}{\beta_i - \gamma_i} \right) - \sum_{i \notin \Gamma} (\beta_i - \gamma_i) + \sum_{i \in \Gamma} \gamma_i + \sum_{i \notin \Gamma} \gamma_i \frac{\beta_i - \gamma_i}{\gamma_i} = 0.$$

209 Therefore, the values in Eq. (S34) are equilibrium values.

210 Similarly, in the specific case $\mu = 0$, the equilibrium value for $J_\emptyset > 0$ in Eq. (S22)
 211 satisfies

$$0 = \left(\sum_{i=1}^n \bar{F}_i \right) \bar{J}_\emptyset + \sum_{i=1}^n \gamma_i \bar{J}_i. \quad (\text{S37})$$

212 Applying Eq. (S36) and dividing by \bar{J}_\emptyset in the right side of the preceding equation
 213 yields

$$\begin{aligned} \left(\sum_{i=1}^n \bar{F}_i \right) + \sum_{i=1}^n \gamma_i \frac{\bar{I}_i}{1 - \bar{I}_i} &= \left(\sum_{i=1}^n (\beta_i - \gamma_i) \right) + \sum_{i=1}^n \gamma_i \frac{\beta_i - \gamma_i}{\gamma_i}, \\ &= 0. \end{aligned}$$

214 Hence, Eq. (S34) is the equilibrium solution of the NiDP model in the specific case
 215 $\mu = 0$.

216 **S1.4.4 Relationship between the NiDP and NiSP models**

217 Assuming all pathogens are interchangeable, Eq. (17) of the main text can be re-
 218 placed by

$$0 = |\Gamma| \hat{F} \bar{J}_{\Omega_i} - ((n - |\Gamma|) \hat{F} + |\Gamma| \hat{\gamma} + 1) \bar{J}_\Gamma + (n - |\Gamma|) \hat{\gamma} \bar{J}_{\Lambda_i}, \quad (\text{S38})$$

219 in which

$$\hat{F} = \hat{\beta} - (\hat{\gamma} + 1). \quad (\text{S39})$$

220 For $1 \leq k < n$, substituting Eq. (19) into Eq. (S38) leads to

$$0 = k \hat{F} \frac{\bar{M}_{k-1}}{C_{k-1}^n} - ((n - k) \hat{F} + k \hat{\gamma} + 1) \frac{\bar{M}_k}{C_k^n} + (n - k) \hat{\gamma} \frac{\bar{M}_{k+1}}{C_{k+1}^n}. \quad (\text{S40})$$

Noting that

$$\frac{C_{k+1}^n}{C_{k-1}^n} = \frac{(n - k + 1)(n - k)}{(k + 1)k} \quad \text{and} \quad \frac{C_{k+1}^n}{C_k^n} = \frac{n - k}{k + 1},$$

221 it follows that

$$0 = (n - k + 1) \hat{F} \bar{M}_{k-1} - ((n - k) \hat{F} + k \hat{\gamma} + 1) \bar{M}_k + (k + 1) \hat{\gamma} \bar{M}_{k+1}, \quad (\text{S41})$$

222 which holds for $1 \leq k < n$ (i.e. there is a total of $n - 1$ such equations).

When $k = n$ the analogue of Eq. (S40) is

$$0 = n\hat{F}\frac{\bar{M}_{n-1}}{C_{n-1}^n} - (n\hat{\gamma} + 1)\frac{\bar{M}_n}{C_n^n},$$

223 and so, since $C_{n-1}^n = n$ and $C_n^n = 1$, it follows that

$$0 = \hat{F}\bar{M}_{n-1} - (n\hat{\gamma} + 1)\bar{M}_n. \quad (\text{S42})$$

224 When $k = 0$ the analogue of Eqn. (S40) obtained by substituting Eq. (20) into
225 Eq. (S29), is

$$-(n\hat{F} + 1)\frac{\bar{M}_0}{C_0^n} + n\hat{\gamma}\frac{\bar{M}_1}{C_1^n} = -1, \quad (\text{S43})$$

226 and so, since $C_1^n = n$ and $C_0^n = 1$, it follows that

$$-(n\hat{F} + 1)\bar{M}_0 + \hat{\gamma}\bar{M}_1 = -1. \quad (\text{S44})$$

227 Taken together, Eqs. (S41-S42-S44) constitute a system of $n + 1$ linear equa-
228 tions that fix the equilibrium prevalences of hosts infected by any number of distinct
229 pathogens in the NiSP model.

230 **Worked example.** When $n = 3$ there is a total of $n + 1 = 4$ classes of host: unin-
231 fected (M_0), singly-infected (M_1), doubly-infected (M_2) and triply-infected (M_3). The
232 equilibrium prevalences can be concatenated into a single vector

$$\mathbf{v} = [\bar{M}_0, \bar{M}_1, \bar{M}_2, \bar{M}_3]^T. \quad (\text{S45})$$

233 If we define \mathbf{b} as

$$\mathbf{b} = [-1, 0, 0, 0]^T, \quad (\text{S46})$$

234 then Eq. (S41-S42-S44) are equivalent to the system of 4 linear equations

$$H\mathbf{v} = \mathbf{b}, \quad (\text{S47})$$

235 in which matrix H equals

$$\begin{bmatrix} -(3F + 1) & \hat{\gamma} & 0 & 0 \\ 3\hat{F} & -(2\hat{F} + \hat{\gamma} + 1) & 2\hat{\gamma} & 0 \\ 0 & 2\hat{F} & -(\hat{F} + 2\hat{\gamma} + 1) & 3\hat{\gamma} \\ 0 & 0 & \hat{F} & -(3\hat{\gamma} + 1) \end{bmatrix}. \quad (\text{S48})$$

236 The equilibrium prevalences of hosts infected by any number of distinct pathogens
237 can then be obtained by solving Eq. (S47).

238 **S1.4.5 Relationship between the NiSP and binomial models**

239 In this subsection, we show that the equilibrium prevalences in the NiSP model with
240 $\mu = 0$ are equal to the expectations under statistical independence, i.e.,

$$\bar{M}_k = C_k^n \bar{I}^k (1 - \bar{I})^{n-k}, \quad (\text{S49})$$

241 in which $\bar{I} = 1 - \gamma/\beta$. In other words, the probability to be infected by k epidemiologically-
242 interchangeable pathogens follows a binomial distribution with parameters n (the
243 number of pathogens considered) and $p = \bar{I}$.

244 In the specific case $\mu = 0$, Eq. (S38) becomes

$$0 = |\Gamma| \bar{F} \bar{J}_{\Omega_i} - ((n - |\Gamma|) \bar{F} + |\Gamma| \gamma) \bar{J}_\Gamma + (n - |\Gamma|) \gamma \bar{J}_{\Lambda_i}, \quad (\text{S50})$$

245 in which $\bar{F} = \beta - \gamma$. Eq. (S41) becomes

$$0 = (n - k + 1) \bar{F} \bar{M}_{k-1} - ((n - k) \bar{F} + k\gamma) \bar{M}_k + (k + 1) \gamma \bar{M}_{k+1}. \quad (\text{S51})$$

246 Eq. (S49) implies

$$\bar{M}_{k-1} = \frac{C_{k-1}^n}{C_k^n} \frac{1 - \bar{I}}{\bar{I}} \bar{M}_k = \frac{k}{n - k + 1} \frac{1 - \bar{I}}{\bar{I}}, \quad \text{and} \quad \bar{M}_{k+1} = \frac{C_{k+1}^n}{C_k^n} \frac{\bar{I}}{1 - \bar{I}} \bar{M}_k = \frac{n - k}{k + 1} \frac{\bar{I}}{1 - \bar{I}} \bar{M}_k. \quad (\text{S52})$$

247 Substituting the values in Eq. (S52) into the right side of Eq. (S51)

$$(n - k + 1) \bar{F} \frac{k}{n - k + 1} \frac{1 - \bar{I}}{\bar{I}} - ((n - k) \bar{F} + k\gamma) + (k + 1) \gamma \frac{n - k}{k + 1} \frac{\bar{I}}{1 - \bar{I}}$$

248 and simplifying leads to:

$$\bar{F}k \frac{1-\bar{I}}{\bar{I}} - (n-k)\bar{F} - k\gamma + \gamma(n-k) \frac{\bar{I}}{1-\bar{I}} = k\gamma - (n-k)\bar{F} - k\gamma + (n-k)\bar{F} = 0.$$

249 Therefore, the values in Eq. (S49) are equilibrium values.

Similarly, in the specific case $\mu = 0$, Eq. (S42) becomes

$$0 = \bar{F}\bar{M}_{n-1} - (n\gamma)\bar{M}_n,$$

250 and substituting the values in Eq. (S52) leads to

$$\bar{F}n \frac{1-\bar{I}}{\bar{I}} - n\gamma = n\gamma - n\gamma = 0.$$

Lastly, in the specific case $\mu = 0$, Eq. (S44) becomes

$$0 = -(n\bar{F})\bar{M}_0 + \gamma\bar{M}_1,$$

251 and substituting the values in Eq. (S52) leads to

$$-n\bar{F} + \gamma n \frac{\bar{I}}{1-\bar{I}} = -n(\beta - \gamma) + n(\beta - \gamma) = 0.$$

252 Hence, Eq. (S49) is the equilibrium solution of the NiSP model in the specific case
253 $\mu = 0$.

254 **S1.4.6 Stochastic models**

255 **Continuous-time Markov chain.** The continuous-time Markov chain model with
256 pathogen-specific clearance rates has four additional events defined in Table S1.

Event number	Event	Rate	Change(s) to state variable(s) (ΔX)
8	Specific clearance of pathogen 1 from host singly-infected by pathogen 2	$\gamma_1 j_1 \Delta t + o(\Delta t)$	$J_1 \rightarrow J_1 - 1$ $J_\emptyset \rightarrow J_\emptyset + 1$
9	Specific clearance of pathogen 2 from host singly-infected by pathogen 1	$\gamma_2 j_2 \Delta t + o(\Delta t)$	$J_2 \rightarrow J_2 - 1$ $J_\emptyset \rightarrow J_\emptyset + 1$
10	Specific clearance of pathogen 1 from co-infected host	$\gamma_1 j_{1,2} \Delta t + o(\Delta t)$	$J_{1,2} \rightarrow J_{1,2} - 1$ $J_2 \rightarrow J_2 + 1$
11	Specific clearance of pathogen 2 from co-infected host	$\gamma_2 j_{1,2} \Delta t + o(\Delta t)$	$J_{1,2} \rightarrow J_{1,2} - 1$ $J_1 \rightarrow J_1 + 1$

Table S1: Additional transitions in the two-pathogen stochastic models.

257 **Stochastic differential equations.** Let $dJ = \tilde{f}dt$ be the unscaled version of the
 258 deterministic model as specified in Eq. (S16-S17). The extension of matrix Σ in
 259 Eq. (24) of the main text, to include pathogen specific clearance is

$$\begin{bmatrix} \mu(N-J_\emptyset) + (F_1 + F_2)J_\emptyset + \gamma_1 J_1 + \gamma_2 J_2 & -F_1 J_\emptyset - (\mu + \gamma_1)J_1 & -F_2 J_\emptyset - (\mu + \gamma_2)J_2 & -\mu J_{1,2} \\ -F_1 J_\emptyset - (\mu + \gamma_1)J_1 & F_1 J_\emptyset + (F_2 + \gamma_1 + \mu)J_1 + \gamma_2 J_{1,2} & 0 & -F_2 J_1 - \gamma_2 J_{1,2} \\ -F_2 J_\emptyset - (\mu + \gamma_2)J_2 & 0 & F_2 J_\emptyset + (F_1 + \gamma_2 + \mu)J_2 + \gamma_1 J_{1,2} & -F_1 J_2 - \gamma_1 J_{1,2} \\ -\mu J_{1,2} & -F_2 J_1 - \gamma_2 J_{1,2} & -F_1 J_2 - \gamma_1 J_{1,2} & F_2 J_1 + F_1 J_2 + (\mu + \gamma_1 + \gamma_2)J_{1,2} \end{bmatrix}, \quad (S53)$$

260 where $N - J_\emptyset = J_1 + J_2 + J_{1,2}$ and N is constant.

261 The new matrix G has dimension 4×11 due to the four additional events in
 262 Table S1, (see Eq. (26)),

$$\begin{aligned} dJ_\emptyset &= \tilde{f}_0 dt - \sqrt{F_1 J_\emptyset} dW_1 - \sqrt{F_2 J_\emptyset} dW_2 + \sqrt{\mu J_1} dW_5 + \sqrt{\mu J_2} dW_6 + \sqrt{\mu J_{1,2}} dW_7 \\ &\quad + \sqrt{\gamma_1 J_1} dW_8 + \sqrt{\gamma_2 J_2} dW_9, \\ dJ_1 &= \tilde{f}_1 dt + \sqrt{F_1 J_\emptyset} dW_1 - \sqrt{F_2 J_1} dW_4 - \sqrt{\mu J_1} dW_5 - \sqrt{\gamma_1 J_1} dW_8 + \sqrt{\gamma_2 J_{1,2}} dW_{11}, \quad (S54) \\ dJ_2 &= \tilde{f}_2 dt + \sqrt{F_2 J_\emptyset} dW_2 - \sqrt{F_1 J_2} dW_3 - \sqrt{\mu J_2} dW_6 - \sqrt{\gamma_2 J_2} dW_9 + \sqrt{\gamma_1 J_{1,2}} dW_{10}, \\ dJ_{1,2} &= \tilde{f}_{1,2} dt + \sqrt{F_1 J_2} dW_3 + \sqrt{F_2 J_1} dW_4 - \sqrt{\mu J_{1,2}} dW_7 - \sqrt{\gamma_1 J_{1,2}} dW_{10} - \sqrt{\gamma_2 J_{1,2}} dW_{11}. \end{aligned}$$

263 **Covariance matrix at the endemic equilibrium.** The new matrices A and B
 264 (Eq. (S4)) are

$$A = \begin{bmatrix} -\beta_1 + \gamma_1 + \mu & 0 \\ 0 & -\beta_2 + \gamma_2 + \mu \end{bmatrix}$$

265 and

$$B = \begin{bmatrix} 2N(\gamma_1 + \mu) \left(1 - \frac{1}{R_{0,1}}\right) & \mu \bar{J}_{12} \\ \mu \bar{J}_{12} & 2N(\gamma_2 + \mu) \left(1 - \frac{1}{R_{0,2}}\right) \end{bmatrix}. \quad (S55)$$

266 The new steady-state covariance matrix \bar{C} (Eq. (S8)) is

$$\bar{C} = \begin{bmatrix} \frac{1}{NR_{0,1}} & \frac{\mu \bar{J}_{1,2}}{N^2[\beta_1 - (\gamma_1 + \mu) + \beta_2 - (\gamma_2 + \mu)]} \\ \frac{\mu \bar{J}_{1,2}}{N^2[\beta_1 - (\gamma_1 + \mu) + \beta_2 - (\gamma_2 + \mu)]} & \frac{1}{NR_{0,2}} \end{bmatrix} \quad (S56)$$

267 where \bar{J}_{12} is defined in Eq. (9) of the main text.

268 The covariance between pathogen 1 and pathogen 2 prevalences (the off-diagonal

269 elements in Eq. (S56)) is

$$\begin{aligned}\bar{C}_{ij} &= \text{cov}\left(\frac{I_1}{N}, \frac{I_2}{N}\right) = \frac{\mu \bar{J}_{1,2}}{N^2[\beta_1 - (\gamma_1 + \mu) + \beta_2 - (\gamma_2 + \mu)]} \\ &= \frac{(\beta_1 + \beta_2)(\beta_1 - \gamma_1 - \mu)(\beta_2 - \gamma_2 - \mu)\mu}{N\beta_1\beta_2(\beta_1 + \beta_2 - \mu)(\beta_1 - \gamma_1 - \mu + \beta_2 - \gamma_2 - \mu)} \geq 0,\end{aligned}$$

270 (for $i \neq j$) with equality if and only if $\mu = 0$ again (assuming $\beta_i > \gamma_i + \mu$, $i = 1, 2$); in
271 the latter case, the deviation from statistical independence is zero (Eq. (9)).

272 In the special case that $\beta_1 = \beta_2 = \beta$ and $\gamma_1 = \gamma_2 = \gamma$,

$$\frac{\partial \bar{C}_{ii}}{\partial \gamma} = -\frac{\mu}{\beta N(2\beta - \mu)} \leq 0,$$

273 meaning that the positive covariance decreases as γ increases (unless $\mu = 0$), as
274 expected.

275 **S1.5 The prevalence of co-infections can be equal to the product of** 276 **the prevalences of interacting pathogens**

277 We consider the same two-pathogen model as Eq. (S16), except we let $\mu = 0$. How-
278 ever, we include two interaction parameters $\sigma_1, \sigma_2 > -1$, such that the forces of
279 infection of both pathogens are

$$F_1 = \beta_1(J_1 + (1 + \sigma_1)J_{1,2}), \quad F_2 = \beta_2(J_2 + (1 + \sigma_2)J_{1,2}). \quad (\text{S57})$$

280 If $\sigma_i < 0$ (resp. > 0), then transmission of pathogen i from a co-infected host is lower
281 (resp. greater) than from singly infected hosts ($i = 1, 2$). With these assumptions,
282 the model is

$$\begin{aligned}j_1 &= F_1 J_\emptyset - (F_2 + \gamma_1)J_1 + \gamma_2 J_{1,2}, \\ j_2 &= F_2 J_\emptyset - (F_1 + \gamma_2)J_2 + \gamma_1 J_{1,2}, \\ j_{1,2} &= F_2 J_1 + F_1 J_2 - (\gamma_1 + \gamma_2)J_{1,2},\end{aligned} \quad (\text{S58})$$

283 where $J_{\emptyset} = 1 - J_1 - J_2 - J_{1,2}$. If we let $I_1 = J_1 + J_{1,2}$ and $I_2 = J_2 + J_{1,2}$, then model (S58)
 284 is equivalent to

$$\begin{aligned} \dot{I}_1 &= \beta_1(I_1 + \sigma_1 J_{1,2})(1 - I_1) - \gamma_1 I_1, \\ \dot{I}_2 &= \beta_2(I_2 + \sigma_2 J_{1,2})(1 - I_2) - \gamma_2 I_2, \\ \dot{J}_{1,2} &= \beta_1(I_1 + \sigma_1 J_{1,2})(I_2 - J_{1,2}) + \beta_2(I_2 + \sigma_2 J_{1,2})(I_1 - J_{1,2}) - (\gamma_1 + \gamma_2)J_{1,2}. \end{aligned} \quad (\text{S59})$$

285 Proceeding as in Supplementary Information, Section S1.1, let $P = I_1 I_2$ and $Z = P -$
 286 $J_{1,2}$. Thus,

$$\dot{Z} = -[\beta_1(I_1 + \sigma_1 J_{1,2}) + \beta_2(I_2 + \sigma_2 J_{1,2}) + \gamma_1 + \gamma_2]Z. \quad (\text{S60})$$

287 Since the expression inside the brackets is positive, $Z(t) \rightarrow 0$ as $t \rightarrow \infty$. The preva-
 288 lence of co-infection by interacting pathogens is asymptotically equal to the product
 289 of their prevalences. Therefore, $Z = 0$ does not imply pathogens do not interact.

290 **S2 Sources of data and side results of model fitting**

291 **S2.1 Additional fitting of the NiSP model**

292 Results of fitting the NiSP model to data from four publications for strains of a sin-
 293 gle pathogen, that may plausibly be assumed epidemiologically-interchangeable
 294 (López-Villavicencio et al., 2007; Seabloom et al., 2009b; Chaturvedi et al., 2011;
 295 Koepfli et al., 2011) are presented in Fig. 3 of the main text. Results for three further
 296 data sets concerning different pathogens of a single host (Andersson et al., 2013;
 297 Moutailler et al., 2016; Nickbakhsh et al., 2016) are in Fig. S1.

298 For convenience the raw data as used in model fitting for these additional data-
 299 sets are re-tabulated in Table S2. Results of model fitting are summarized in Table S3.
 300 Ambiguities needed to be resolved in collating these data from what is reported in
 301 the original publications. The data presented in Moutailler et al. (2016) are inconsis-
 302 tent, in as much as it is reported that a total of 267 ticks were tested, but the per-
 303 centage data in the section “Co-infections and associations between pathogens” of
 304 the paper instead indicate 262 is the correct total. We have used the value 262 here.
 305 Misreporting of the number of uninfected hosts in reference Seabloom et al. (2009b)
 306 has been corrected by reference to the original data (Seabloom et al., 2009a) after

Pathogens with n distinct types, strains or clones	n	Observed counts, O_k									Total N	
		0	1	2	3	4	5	6	7	8		9
Pathogens of <i>Ixodes ricinus</i> ticks	37	147	66	24	18	5	2	-	-	-	-	262
Barley and cereal yellow dwarf viruses	5	1570	224	69	17	6	4	-	-	-	-	1890
Respiratory viruses	11	17630	8568	964	105	15	2	-	-	-	-	27284

Table S2: Sources of data for fitting the NiSP model in which pathogen species, clones or strains are assumed to be epidemiologically-interchangeable. The data sets include pathogens of *I. ricinus* ticks (Moutailler et al., 2016), barley yellow dwarf viruses (Seabloom et al., 2009b), respiratory viruses (Nickbakhsh et al., 2016).

	NiSP		Binomial		$\Delta AIC=2\Delta L$	GoF p
	R_0	L	p	L		
Pathogens of <i>Ixodes ricinus</i> ticks	1.021	-314.1	0.020	-329.3	30.5	0.476
Barley and cereal yellow dwarf viruses	1.051	-1180.8	0.048	-1261.9	162.2	0.000
Respiratory viruses	1.037	-22619.0	0.036	-21731.9	-1774.2	0.000

Table S3: Fitting the NiSP model. The NiSP model was highly supported over the binomial model ($\Delta AIC \gg 10$) in all cases tested but one (respiratory viruses), where the binomial model is highly supported over the NiSP model. The final column of the table – GoF – corresponds to the goodness-of-fit test of the NiSP model; values $p > 0.05$ correspond to lack of evidence for failure to fit the data, and so the NiSP model is adequate for the data concerning pathogens of *Ixodes ricinus* ticks (Moutailler et al., 2016).




Figure S1: Comparing the best-fitting NiSP model with a binomial model (i.e. statistical independence) for: (A) Pathogens of *Ixodes ricinus* ticks (Moutailler et al., 2016); (B) Barley and cereal yellow dwarf viruses (Seabloom et al., 2009b); (C) Human respiratory viruses (Nickbakhsh et al., 2016). Insets to each panel show a “zoomed-in” section of the graph corresponding to high multiplicities of pathogen co-infection. Asterisks indicate predicted counts smaller than 0.1. For the data shown in (A), there is no evidence that the NiSP model does not fit the data, and so our test indicates the pathogens do not interact. For the data shown in (B), although the NiSP model is a better fit to the data than the binomial model, there is evidence of lack of goodness-of-fit, and so our test indicates these pathogens interact (or are epidemiologically different). For the data shown in (C), although the binomial model is a better fit to the data than the NiSP model, there is evidence of lack of goodness-of-fit, and again it can be concluded that these pathogens interact (or are epidemiologically different).

308 **S2.2 Fitting the NiDP model**

309 **S2.2.1 Sources of data**

310 Howard et al. (2001) report results of analyzing 73 data sets concerning multiple
311 *Plasmodium* spp. causing malaria (rows 68–140 of Table 1 in that paper). We re-
312 analyzed the subset of these studies satisfying the additional constraints that they
313 considered:

- 314 • interactions between three *Plasmodium* species (omits 16 rows corresponding
315 to only two pathogens, viz. 73, 81, 86, 89-92, 104, 105, 107, 110, 120, 126,
316 134 and 139-140, as well as 2 rows corresponding to four pathogens, viz. 125
317 and 128);
- 318 • disease status of at least 100 individuals (omits 8 rows, viz. 72, 85, 87, 115,
319 129, 135, 136 and 138).

320 These constraints were imposed simply to reduce the number of studies, rather than
321 because our methodology could not handle such data. We also omitted six of the
322 remaining data sets – rows 83, 93, 94, 121, 122 and 131 – since we found it impos-
323 sible to unambiguously reconcile the data as reported in the publication to counts
324 of different types of infection. Most often this was because the data were reported
325 as percentages rounded to a small number of significant figures, which did not un-
326 ambiguously specify the raw number of individuals infected by each combination of
327 pathogens. This left a final total of 41 data sets taken from 35 distinct papers: 24
328 data sets considering the three-way interaction between *P. falciparum*, *P. malariae*
329 and *P. vivax* (denoted FMV in Howard et al. (2001)) and 17 data sets considering the
330 three-way interaction between *P. falciparum*, *P. malariae* and *P. ovale* (denoted FMO
331 in Howard et al. (2001)). The data sets are re-tabulated for convenience in Table S4.

332 **S2.2.2 Recreating the analyses of Howard et al. (2001)**

333 We did not explicitly recreate the analysis based on log-linear models as presented
334 by Howard et al. (2001), since no information was given in the paper on how to
335 handle sampling zeros (i.e. cases in which within an individual data set the count
336 of individual infected by a particular combinations of pathogens is zero). Given the

		N	Observed counts, O _r							
			∅	F	M	V	FM	FX	MX	FMX
74	Léger et al. (1923)	250	83	111	49	1	6	0	0	0
75	Bédier et al. (1924)	135	45	58	27	3	2	0	0	0
76	Knowles and White (1930)	809	642	149	12	1	2	2	0	1
82 (!)	Dorolle (1927)	652	232	258	64	54	32	12	0	0
84	Phillips (1923)*	645	409	112	10	109	0	4	1	0
88	Lalor (1913)*	207	94	47	21	40	0	3	2	0
106	Wilson (1936)	3393	1784	1103	87	19	244	63	2	91
108 (!)	Borel and Levanan (1927)	1249	885	227	23	92	3	16	3	0
109 (!)	Borel and Levanan (1927)	1022	947	19	12	39	0	4	1	0
111	Banerjea (1930)*	1519	578	225	7	668	0	41	0	0
112	Khambata (1913)*	112	72	26	8	4	0	1	1	0
113	Ramsay (1928)*	1514	1073	268	9	160	0	3	1	0
114	Bailey (1928)*	1068	547	396	67	35	18	5	0	0
116	Masterman (1913)	700	238	317	75	55	4	9	2	0
117	Angus (1919)*	40168	28936	2614	9	8483	0	126	0	0
118	Gordon et al. (1991)	268	208	14	6	30	1	6	3	0
119	Lalor (1912)*	151	52	38	13	33	4	6	4	1
123	Carter (1927)*	11260	9510	170	568	986	2	4	19	1
124	Schnuffer (1938)	3266	2148	593	234	196	42	30	15	8
127	Banchongaksorn et al. (1996)	913	487	221	5	179	0	21	0	0
130	Treadgold (1918)	540	396	3	1	136	0	4	0	0
132	Collins et al. (1988)	614	407	151	11	19	3	21	2	0
133	Mizushima et al. (1994)	506	231	144	0	81	1	39	4	6
137	United Fruit Co. (1925)*	2742	1973	435	14	299	0	21	0	0
68	Campbell et al. (1987)	147	77	56	0	1	11	1	0	1
69	Campbell et al. (1987)	142	26	68	3	0	40	4	0	1
70	Campbell et al. (1987)	196	41	112	2	0	25	10	0	6
71	May et al. (1997)	230	40	123	1	0	32	7	0	27
77	Alifrangis et al. (1999)	126	5	72	2	0	31	13	0	3
78	Hellgren et al. (1994)	163	32	105	5	0	20	1	0	0
79	Thomson et al. (1994)	1465	770	641	17	2	30	5	0	0
80	Gbary et al. (1988)	735	444	234	22	7	20	7	1	0
95	Deloron et al. (1989)	1465	770	641	17	2	30	5	0	0
96	Deloron et al. (1989)	245	130	95	0	0	16	4	0	0
97	Deloron et al. (1989)	253	126	109	4	0	13	0	0	1
98	Deloron et al. (1989)	225	136	82	0	0	3	4	0	0
99	May et al. (1997)	159	97	56	0	1	3	2	0	0
100	Trape et al. (1992)	2465	2372	85	6	0	1	1	0	0
101	Trape et al. (1994)	8539	2208	4254	133	50	1435	227	3	229
102	Molineaux et al. (1980)	7026	2658	3295	143	36	742	108	6	38
103	Molineaux et al. (1980)	6526	3474	2015	183	15	757	42	2	38

Table S4: Data sets as extracted from the source references for studies focusing on interactions between *P. falciparum*, *P. malariae* and either *P. vivax* (i.e. FMV) or *P. ovale* (i.e. FMO). The asterisks indicate that the corresponding data sets were extracted from (Knowles and White, 1930). The number in the left-most column shows the number of the relevant row in Table 1 of Howard et al. (2001). The rows with (!) correspond to studies for which the total number of individuals sampled as reported by Howard et al. (2001) do not match what we found on interrogating the original paper; in all cases, we used the corrected values as shown in the table. Note that many of the references are to Knowles and White (1930); this corresponds to cases for which the data from the originally-listed source were extracted from the large compendium collated in 1930 by Knowles & White. The notation X (in FX, MX, or FMX) corresponds either to V (i.e. *P. vivax*, upper part of the table, data sets 74–137) or to O (i.e. *P. ovale*, lower part of the table, data sets 68–103).

337 small size of many of the studies, this was quite common, affecting 34 of these
338 41 data sets. The statistical difficulty is that at least one of the models involved in
339 the model selection procedure cannot then reliably be estimated, since an estimated
340 coefficient in a Poisson regression model tends to negative infinity. In turn this means
341 that model selection based on log-likelihood ratio tests breaks down (Fienberg and
342 Rinaldo, 2012). How such sampling zeros affect log-linear models with sparse data
343 sets is an active area of current research in the methodological statistical literature,
344 e.g. (Fienberg and Rinaldo, 2012). It is unclear from what is presented in Howard
345 et al. (2001) precisely how such cases were handled; correspondence with those
346 authors we could contact also did not reveal what precisely had been done in the
347 original analysis (personal communication Prof. Christl Donnelly). We note that,
348 since our methods are based on multinomial sampling rather than Poisson counts,
349 statistical difficulties surrounding sampling zeros simply do not affect our analyses.

350 **S2.3 Fitting the models with specific clearance**

351 **S2.3.1 Fitting the models**

352 All models were fitted after transformation to allow only biologically-meaningful val-
353 ues of parameters, by estimating $\log(\hat{\gamma}_i)$ to ensure only positive values of $\hat{\gamma}_i$ are
354 permissible, and using these to estimate the infection rates after transformation,
355 with $\log(\hat{\beta}_i/(\hat{\gamma}_i + 1) - 1)$ (which ensures $R_{0,i} > 1$).

356 However, we noticed that this estimation method may return extremely high val-
357 ues of $\hat{\gamma}$ and $\hat{\beta}$ in the NiSP model. This is because we scaled β and γ relative to μ ,
358 while the optimal value of μ may be zero. The specific case $\mu = 0$ corresponds to
359 statistical independence (see Sections S1.4.3 and S1.4.5). When the data look sta-
360 tistically independent, the estimation algorithm may diverge. For this reason, we did
361 not explore parameter estimation in the NiDP model with $\gamma > 0$ for the malaria data,
362 as its treatment would have required specific considerations that felt beyond the
363 scope of this paper, since our purpose is not to draw conclusions about interaction
364 among malaria species.

365 **S2.3.2 Results of fitting the two-parameter NiSP model**

366 Results of model fitting are summarized in Table S5.

	NiSP (β only)		NiSP (β & γ)			Model selection		Binomial		Δ AIC	GoF p
	β	L	β	γ	L	χ^2	p	p	L		
Human papillomavirus	1.032	-6580.9	1.178	0.142	-6573.1	7.794	0.005	0.031	-6868.8	589.3	0.986
Pathogens of <i>I. ricinus</i> ticks	1.021	-314.1	1.161	0.137	-313.7	0.360	0.549	0.020	-329.3	30.5	0.476
Anther smut (<i>M. violaceum</i>)	1.009	-611.4	1.009	0.000	-611.4	0.000	1.000	0.009	-690.8	158.8	0.000
Barley yellow dwarf viruses	1.051	-1180.8	1.051	0.000	-1180.8	0.000	1.000	0.048	-1261.9	162.2	0.000
<i>Borrelia afzelii</i> on bank voles	1.044	-652.1	1.044	0.000	-652.1	0.000	1.000	0.040	-799.0	293.8	0.000
Malaria (<i>Plasmodium vivax</i>)	1.021	-3169.2	1.162	0.138	-3164.6	4.588	0.032	0.021	-3467.3	603.5	0.000
Respiratory viruses	1.037	-22619.0	4.7×10^9	4.6×10^9	-21731.9	887.057	0.000	0.036	-21731.9	-2.0	0.000

Table S5: Fitting the NiSP model to data sets corresponding to human papillomavirus (Chaturvedi et al., 2011), pathogens of *I. ricinus* ticks (Moutailler et al., 2016), anther smut (*M. violaceum*) (López-Villavicencio et al., 2007), barley yellow dwarf viruses (Seabloom et al., 2009b), *Borrelia afzelii* on bank voles (Andersson et al., 2013), malaria (*Plasmodium vivax*) (Koepfli et al., 2011), respiratory viruses (Nickbakhsh et al., 2016). Parameters for the best-fitting variant of the NiSP model for each pathogen species, strain or clone are highlighted in bold; the two-parameter model is supported in cases for which $p < 0.05$ in the Model Selection part of the table (including human papillomavirus and malaria (*Plasmodium vivax*)). The NiSP model was highly supported over the binomial model (Δ AIC $\gg 10$) in all cases tested but one (Respiratory viruses). The final column of the table – GoF – corresponds to the goodness-of-fit test of the best-fitting model; values $p > 0.05$ correspond to lack of evidence for failure to fit the data, and so the NiSP model is adequate for the data concerning human papillomavirus and pathogens of *Ixodes ricinus* ticks. These results are qualitatively identical to those for the model without specific-clearance as presented in the main text. Note that in the NiSP model, β and γ are scaled relative to μ . This is why β and γ of NiDP reach extremely high values for respiratory viruses. Parameter estimation tends to $\mu = 0$, which actually corresponds to the binomial model, which has one fewer parameter (see Section S1.4.5 and Fig. S2). Hence Δ AIC = -2 for Respiratory viruses, since the NiSP model requires one additional parameter compared to the binomial model.




Figure S2: Comparing the best-fitting two-parameter NiSP model with a binomial model (i.e. statistical independence) for human respiratory viruses (Nickbakhsh et al., 2016). Insets to each panel show a “zoomed-in” section of the graph corresponding to high multiplicities of pathogen co-infection. This figure shows that the best-fitting NiSP model converges to the binomial model in this case (which is a special case of NiSP for $\mu = 0$, see section S1.4.5).

367 Models were fitted by maximum likelihood, with model selection done via χ^2 tests
368 on the likelihood-ratio (Bolker, 2008) or the Akaike Information Criterion (Sakamoto
369 et al., 1986), depending on whether or not models were nested.

370 **S2.3.3 Fitting the NiDP model with specific clearance**

371 Estimated parameters occasionally diverge in the more complex version of the NiSP
372 model with specific clearance, and very large numeric values of best-fitting epidemi-
373 ological parameters can be obtained (but a reasonable value of R_0). Exploratory
374 investigations suggested that fitting the NiDP model with specific clearance to the
375 malaria data was affected by this type of identifiability issue, and so would therefore
376 have required a specific treatment. Since our purpose here was not to draw conclu-
377 sions about interactions among malaria species, but instead to show the utility of
378 our overall approach, we did not pursue this analysis further.

379 **References**

- 380 Alifrangis, M., Lemnce, M., Moon, R., Theisen, M., Bygbjerg, B., Ridley, R., and Jakob-
381 sen, P. (1999). IgG reactivities against recombinant Rhoptry-Associated Protein-1
382 (rRAP-1) are associated with mixed Plasmodium infections and protection against
383 disease in Tanzanian children. *Parasitology*, 119:337–342.
- 384 Andersson, M., Scherman, K., and Råberg, L. (2013). Multiple-strain infections of
385 *Borrelia afzelii*: a role for within-host interactions in the maintenance of antigenic
386 diversity? *The American Naturalist*, 181:545–554.
- 387 Banchongaksorn, T., Yomokgul, P., Panyim, S., Rooney, W., and Vickers, P. (1996). A
388 field trial of the ParaSight–Ftest for the diagnosis of *Plasmodium falciparum* infec-
389 tion. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 90:244–
390 245.
- 391 Bédier, E., Laruency, and Baurly (1924). Index endémique du paludisme à Niamey
392 à la fin de la saison des pluies. *Bulletin de la Société de Pathologie Exotique*,
393 XVII:327.

394 Bolker, B. (2008). *Ecological Models and Data in R*. Princeton University Press, New
395 Jersey.

396 Borel, P. and Levanan (1927). Le paludisme à Saïgon. *Bulletin de la Société de*
397 *Pathologie Exotique*, XX:94.

398 Campbell, G., Collins, F., Brandling-Bennett, A., Schwartz, I., and Roberts, J. (1987).
399 Age-specific prevalence of antibody to a synthetic peptide of the circumsporozoite
400 protein of *Plasmodium falciparum* in children from three villages in Kenya. *Ameri-*
401 *can Journal of Tropical Medicine and Hygiene*, 39:220–224.

402 Chaturvedi, A. K., Katki, H. A., Hildesheim, A., Rodríguez, A. C., Quint, W., Schiffman,
403 M., Van Doorn, L.-J., Porras, C., Wacholder, S., Gonzalez, P., et al. (2011). Human
404 papillomavirus infection with multiple types: pattern of coinfection and risk of cer-
405 vical disease. *The Journal of Infectious Diseases*, 203:910–920.

406 Collins, W., Cattani, J., Lourie, J., Taufa, T., Anderson, W., Skinner, J., Stanfill, P., and
407 Huong, A. (1988). Antibody responses to malarial antigens in the Wopkaimin pop-
408 ulation of the star mountains, Papua New Guinea. *American Journal of Tropical*
409 *Medicine and Hygiene*, 39:241–245.

410 Deloron, P., Campbell, G., Brandling-Bennett, D., Roberts, J., Schwartz, I., Odera, J.,
411 Lai, A., Osanga, C., Cruz, V., and McCutchan, T. (1989). Antibodies to *Plasmod-*
412 *ium falciparum* ring-infected erythrocyte surface antigen and *P. falciparum* and
413 *P. malariae* circumsporozoite proteins: seasonal prevalence in Kenyan villages.
414 *American Journal of Tropical Medicine and Hygiene*, 41:393–399.

415 Dorolle, P. (1927). Le paludisme à Hagiang (Tonkin). *Bulletin de la Société de Patholo-*
416 *gie Exotique*, XX:895.

417 Fienberg, S. E. and Rinaldo, A. (2012). Maximum likelihood estimation in log-linear
418 models. *The Annals of Statistics*, 40:996–1023.

419 Gbary, A., Guiguemdé, T., and Ouedraogo, J. (1988). Emergence of chloroquine
420 resistant malaria in West Africa: the case of Sokode in Togo. *Tropical Medicine and*
421 *Parasitology*, 39:142–144.

- 422 Gordon, D., Davis, D., Lee, M., Lambros, C., Harrison, B., Samuel, R., Campbell, G.,
423 Selvarajan, K., and Lewis, G. (1991). Significance of circumsporozoite-specific anti-
424 body in the natural transmission of *Plasmodium falciparum*, *Plasmodium vivax* and
425 *Plasmodium malariae* in an aboriginal (Orang Asli) population of central peninsular
426 Malaysia. *American Journal of Tropical Medicine and Hygiene*, 45:49–56.
- 427 Hellgren, U., Ericsson, O., Kihamia, C., and Rombo, L. (1994). Malaria parasites and
428 chloroquine concentrations in Tanzanian schoolchildren. *Tropical Medicine and*
429 *Parasitology*, 45:293–297.
- 430 Howard, S., Donnelly, C., and Chan, M.-S. (2001). Methods for estimation of associa-
431 tions between multiple species parasite infections. *Parasitology*, 122:233–251.
- 432 Knowles, R. and White, R. (1930). Studies in the parasitology of malaria. *Indian*
433 *Medical Research Memoirs*, 18:1–436.
- 434 Koepfli, C., Ross, A., Kiniboro, B., Smith, T. A., Zimmerman, P. A., Siba, P., Mueller, I.,
435 and Felger, I. (2011). Multiplicity and diversity of *Plasmodium vivax* infections in
436 a highly endemic region in Papua New Guinea. *PLoS Neglected Tropical Diseases*,
437 12:e1424.
- 438 Léger, M., Pinaud, J., and Bédier, E. (1923). Le paludisme à Zinder: index héma-
439 tologique. *Bulletin de la Société de Pathologie Exotique*, XVI:137.
- 440 López-Villavicencio, M., Jonot, O., Coantic, A., Hood, M. E., Enjalbert, J., and Giraud, T.
441 (2007). Multiple infections by the anther smut pathogen are frequent and involve
442 related strains. *PLoS Pathogens*, 3:e176.
- 443 Masterman, E. (1913). Notes on some tropical diseases of Palestine. *Journal of*
444 *Hygiene*, XIII:49.
- 445 May, J., Mockenhaupt, F., Ademowo, O., Falusi, A., Olumese, P., Bienzle, U., and
446 Meyer, C. (1997). High rate of mixed and subpatent malarial infections in south-
447 west Nigeria. *American Journal of Tropical Medicine and Hygiene*, 61:339–343.
- 448 May, R. M. and Nowak, M. A. (1995). Coinfection and the evolution of parasite viru-
449 lence. *Proceedings of the Royal Society, B*, 261:209–215.

- 450 Mizushima, Y., Kato, H., Ohmae, H., Tanaka, T., Bobogare, A., and Ishii, A. (1994).
451 Prevalence of malaria and its relationship to anemia, blood glucose levels, and
452 serum somatomedin c (IGF-1) levels in the Solomon Islands. *Acta Tropica*, 58:207–
453 220.
- 454 Molineaux, L., Storey, J., Cohen, J., and Thomas, A. (1980). A longitudinal study of
455 natural malaria in the West African Savanna in the absence of control measures:
456 relationships between different *Plasmodium* species, in particular *P. falciparum*
457 and *P. malariae*. *American Journal of Tropical Medicine and Hygiene*, 29:725–737.
- 458 Moutailler, S., Valiente Moro, C., Vaumourin, E., Michelet, L., Tran, F. H., Devillers, E.,
459 Cosson, J.-F., Gasqui, P., Van, V. T., Mavingui, P., Vourc'h, G., and Vayssier-Taussat,
460 M. (2016). Co-infection of ticks: the rule rather than the exception. *PLoS Neglected*
461 *Tropical Diseases*, 10:1–17.
- 462 Nickbakhsh, S., Thorburn, F., Von Wissmann, B., McMenamin, J., Gunson, R., and
463 Murcia, P. (2016). Extensive multiplex PCR diagnostics reveal new insights into the
464 epidemiology of viral respiratory infections. *Epidemiology & Infection*, 144:2064–
465 2076.
- 466 O’Dea, E. B., Park, A. W., and Drake, J. M. (2018). Estimating the distance to an
467 epidemic threshold. *Journal of the Royal Society: Interface*, 15:20180034.
- 468 Plemmons, R. J. (1977). M-matrix characterizations. I—nonsingular M-matrices. *Lin-*
469 *ear Algebra and its Applications*, 18:175–188.
- 470 Sakamoto, Y., Ishiguro, M., and Kitagawa, G. (1986). *Akaike Information Criterion*
471 *Statistics*. D. Reidel Publishing Company, Dordrecht.
- 472 Schnuffer, W. (1938). Two subjects relating to the epidemiology of malaria. *Journal*
473 *of the Malaria Institute of India*, 1:221–256.
- 474 Seabloom, E. W., Hosseini, P. R., Power, A. G., and Borer, E. T. (2009a). Data from:
475 Diversity and composition of viral communities: coinfection of barley and cereal
476 yellow dwarf viruses in California grasslands (doi:10.5061/dryad.2bj836).
- 477 Seabloom, E. W., Hosseini, P. R., Power, A. G., and Borer, E. T. (2009b). Diversity and

478 composition of viral communities: coinfection of barley and cereal yellow dwarf
479 viruses in California grasslands. *The American Naturalist*, 173:E79–E98.

480 Thomson, M., D’Alessandro, U., Bennett, S., Connor, S., Langerock, P., Jawara, M.,
481 Todd, J., and Greenwood, B. (1994). Malaria prevalence is inversely related to
482 vector density in The Gambia, West Africa. *Transactions of the Royal Society of*
483 *Tropical Medicine and Hygiene*, 88:638–643.

484 Trape, J., Lefebvre-Zante, E., Legros, F., Ndiaye, G., Bouganali, H., Druilhe, P., and
485 Salam, G. (1992). Vector density gradients and the epidemiology of urban malaria
486 in Dakar, Senegal. *American Journal of Tropical Medicine and Hygiene*, 47:181–
487 189.

488 Trape, J., Rogier, C., Konate, L., Diagne, N., Bouganali, H., Canque, B., Legros, F.,
489 Badji, A., Ndiaye, G., Brahimi, K., Faye, O., Druilhe, P., and Pereire da Silva, L.
490 (1994). The Dielmo project: a longitudinal study of natural malaria infection and
491 the mechanisms of protective immunity in a community living in a holoendemic
492 area of Senegal. *American Journal of Tropical Medicine and Hygiene*, 51:123–137.

493 Treadgold, C. (1918). Malaria in Macedonia with especial reference to the use of
494 prophylactic quinine. *Journal of the Royal Army Medical Corps*, 30:571–586.

495 Van Kampen, N. G. (1992). *Stochastic Processes in Physics and Chemistry*. Elsevier.

496 Wilson, D. (1936). Rural hyper-endemic malaria in Tanganyika territory. *Transactions*
497 *of the Royal Society of Tropical Medicine and Hygiene*, 29:583–618.